Why Is Eliquis So Expensive?
By BetterBuyRx Editorial Team
Written for cost and savings education only, not medical advice, and not medically reviewed. Always confirm details with your doctor or pharmacist. See our methodology.
Last updated
Eliquis (apixaban) listed at $521 for a 30-day supply in 2023, per CMS, even though the FDA approved generic versions back in December 2019. The reason it still costs hundreds of dollars at a U.S. counter in 2026 is not manufacturing cost, which is modest for a small-molecule tablet. It's a stack of legal and market structures: patent protection extended through litigation settlements, no domestic generic competition, and a rebate system that inflates list prices. Each layer is worth understanding, because each has a different escape hatch.
Layer 1: The patent wall (and the 2028 date)
The FDA approved the first generic apixaban applications in December 2019: Micro Labs and Mylan, the first generics of any direct oral anticoagulant. Approval, however, only means the copies passed FDA's standards. Bristol Myers Squibb and Pfizer then defended Eliquis's composition-of-matter patents in court, won a key ruling upheld on appeal in 2021, and settled with generic challengers on confidential terms. The manufacturers have publicly indicated generics won't launch before April 1, 2028, subject to further challenges. Until then, every U.S. pharmacy fill is brand Eliquis at brand pricing.
This is the standard blockbuster pattern: Lipitor, Zocor, and Crestor all held high prices until their patents lapsed, then collapsed to a few dollars a month within a few years of generic entry, the story we tell in why atorvastatin is so cheap now. Apixaban is queued for the same cliff; it just hasn't fallen yet.
Layer 2: No competition within the fill
Even without a true generic, prices can fall when therapeutic competitors fight for formulary position. But the direct oral anticoagulant (DOAC) market is a comfortable duopoly: Eliquis and Xarelto dominate, both on-patent for most of their run, with little incentive to undercut each other. The older alternative, warfarin, is pennies per tablet ($3.33/month at Hippo · Walmart in BetterBuyRx's July 2026 snapshot) but requires regular INR blood monitoring and is clinically different; MedlinePlus outlines apixaban's role. Anticoagulant switching is never a do-it-yourself savings move; stopping raises stroke risk.
Layer 3: List prices, rebates, and why the sticker keeps rising
Eliquis's list price climbed steadily for years. Part of the mechanism, documented across the industry in the FTC's interim report on pharmacy benefit managers, is that manufacturers raise list prices partly to fund the rebates PBMs demand for formulary placement. Insured patients whose coinsurance is calculated off the *list* price (and cash payers who face it directly) absorb the spread. Our explainer on what a PBM is unpacks the incentives.
What actually changed: Medicare negotiation
The Inflation Reduction Act made Eliquis one of the first ten drugs subject to Medicare price negotiation. Effective 2026, the negotiated price is $231 per 30-day supply, 56% off the 2023 list price, per CMS. Paired with the $2,100 Part D out-of-pocket cap for 2026, Medicare patients now have a bounded worst case; see the Part D cap guide. The negotiated price does *not* apply to commercial insurance or cash purchases.
Meanwhile: what non-Medicare patients can do
- Verified international pricing: In BetterBuyRx's July 2026 snapshot, licensed international mail-order pharmacies quoted apixaban/Eliquis at $90.00 to $190.99 per month; details, caveats, and shipping realities in Eliquis cost without insurance.
- Manufacturer programs: BMS patient assistance can supply Eliquis free to eligible uninsured patients; see patient assistance programs.
- Watch the calendar: if the 2028 generic entry holds, apixaban's cash price should begin the same multi-year slide every post-patent blockbuster has taken. Track live Eliquis prices; we update from real quotes, not estimates.
Frequently asked questions
Why is Eliquis still expensive if a generic was approved in 2019?
FDA approval and market entry are separate events. Generic manufacturers won approval in December 2019, but patent litigation ended in settlements that keep generics off the U.S. market; the manufacturers have indicated no launch before April 2028, subject to further legal challenges.
When will Eliquis go generic in the U.S.?
Based on publicly reported patent settlement terms, generic apixaban is not expected at U.S. pharmacies before April 2028. Timelines can shift with litigation, so treat any specific date as provisional.
Did Medicare negotiation lower the Eliquis price?
Yes, for Medicare enrollees: CMS negotiated Eliquis down to $231 for a 30-day supply effective 2026, 56% below its 2023 list price of $521. The negotiated price applies to Medicare drug plans, not to cash or commercially insured purchases.
Why doesn't a discount card make Eliquis cheap?
Discount cards negotiate off pharmacy list prices, which works well for competitive generics. For a single-source brand like Eliquis, there's no competition to harness; cards typically shave modest percentages off a very high base.
Sources
Compare prices & find savings
This guide is for cost and savings education only. It is not medical advice. Talk to your doctor or pharmacist before making any changes to your medications. Prices vary by pharmacy, location, quantity, and eligibility, and they change over time.
Related guides
- Why Is My Medication So Expensive?
The real reasons a prescription can cost more than expected, from insurance tiers to PBM markups, plus what you can do about it.
- What Is a PBM? How Pharmacy Benefit Managers Affect Prices
Learn what a pharmacy benefit manager does, how PBMs shape drug prices and formularies, and what the FTC found about their role in the market.
- Patient Assistance Programs: Who Qualifies and How to Apply
How manufacturer and nonprofit patient assistance programs work, who typically qualifies by income, and what documents you need to apply.
- Medicare Part D Costs in 2026: The Out-of-Pocket Cap Explained
Learn how the $2,100 Medicare Part D out-of-pocket cap works in 2026, what counts toward it, and how it changed from prior years.